AKP06

AKP06 is a nutraceutical candidate currently in development by Akademy Pharma, a division of the Italian pharmaceutical company Damor Farmaceutici. Positioned within the company's metabolic health pipeline, AKP06 is intended for the management of metabolic disorders. While it is listed alongside other nutraceutical projects like LopiGLIK (AKP01) and Zinutrik (AKP02), specific information regarding its chemical composition, active ingredients, and precise mechanism of action remains proprietary and has not been publicly disclosed. The product is categorized as a nutraceutical or dietary supplement rather than a conventional pharmaceutical drug, and it is listed in the company's pipeline with a development completion percentage rather than traditional clinical trial phases.